Search alternatives:
largest decrease » larger decrease (Expand Search)
values decrease » values increased (Expand Search)
marked decrease » marked increase (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
22 non » 32 non (Expand Search), 24 non (Expand Search)
largest decrease » larger decrease (Expand Search)
values decrease » values increased (Expand Search)
marked decrease » marked increase (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
22 non » 32 non (Expand Search), 24 non (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
15
Video 1_The clinical application value of mixed reality in robotic laparoscopic partial nephrectomy.mp4
Published 2024“…All patients underwent mid-abdominal CT plain scans and enhancements. The MR group utilized three-dimensional reconstruction of CT data and employed 3D tablets and HoloLens glasses for preoperative discussions, surgical planning, and intraoperative guidance. …”
-
16
-
17
-
18
-
19
-
20
Annual treatment frequencies in recurrence and non-recurrence groups.
Published 2025“…These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”